Cargando…

Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases

INTRODUCTION: The brain is a frequent site of metastases in NSCLC, and screening for asymptomatic brain metastases (BM) is increasingly advised in NSCLC guidelines. An asymptomatic BM diagnosis may trigger anxiety for future neurologic problems and can negatively affect quality of life of patients a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoenmaekers, Janna J.A. O., Bruinsma, Jeroen, Wolfs, Claire, Barberio, Lidia, Brouns, Anita, Dingemans, Anne-Marie C., Hendriks, Lizza E.L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516448/ https://www.ncbi.nlm.nih.gov/pubmed/36188631 http://dx.doi.org/10.1016/j.jtocrr.2022.100401

Ejemplares similares

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
por: Schoenmaekers, Janna Josephus Anna Oda, et al.
Publicado: (2020)

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review
por: Brouns, Anita, et al.
Publicado: (2021)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC
por: Keek, Simon A., et al.
Publicado: (2022)

Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions
por: Hartgerink, Dianne, et al.
Publicado: (2018)

Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment
por: Hendriks, Lizza E. L., et al.
Publicado: (2018)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation
por: Witlox, Willem J. A., et al.
Publicado: (2018)

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery
por: Gao, Hong Xiang, et al.
Publicado: (2018)

Predictive effect of DCE-MRI and DWI in brain metastases from NSCLC
por: Ye, Chengyu, et al.
Publicado: (2021)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
por: Nicoś, Marcin, et al.
Publicado: (2022)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Brain metastases
por: Plowman, Nick
Publicado: (2012)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
por: Ikarashi, Daiki, et al.
Publicado: (2021)

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
por: Laakmann, Elena, et al.
Publicado: (2020)

From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC
por: Protopapa, Maria, et al.
Publicado: (2019)

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study
por: Hu, Nan, et al.
Publicado: (2015)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases
por: Wong, Philip, et al.
Publicado: (2023)

Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zeng, Haiyan, et al.
Publicado: (2022)

Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
por: Wang, Yu, et al.
Publicado: (2023)

Imaging of brain metastases
por: Fink, Kathleen R., et al.
Publicado: (2013)

Neuropathology of brain metastases
por: Pekmezci, Melike, et al.
Publicado: (2013)

Surgery for brain metastases
por: Yaeger, Kurt Andrew, et al.
Publicado: (2013)

Prevention of Brain Metastases
por: Bovi, Joseph A.
Publicado: (2018)

Brain metastases: It takes two factors for a primary cancer to metastasize to brain
por: Liu, Dingyun, et al.
Publicado: (2022)

Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancer
por: Brouns, Anita J.W.M., et al.
Publicado: (2023)

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases
por: Luo, Shuimei, et al.
Publicado: (2015)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis
por: Milano, Michael T, et al.
Publicado: (2020)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2s1oe54bmt9k54n9uk878aefhq